Pharmaceutical Technology41 分钟
RioDerm-002 by Rion for Radiation Injury: Likelihood of Approval
RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...
Pharmaceutical Technology19 小时
Trientine hydrochloride by Innolife for Systolic Heart Failure: Likelihood of Approval
Trientine hydrochloride is under clinical development by Innolife and currently in Phase II for Systolic Heart Failure. According to GlobalData, Phase II drugs for Systolic Heart Failure have a 67% ...
Pharmaceutical Technology8 小时
AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment
AstraZeneca and Daiichi Sankyo have withdrawn marketing authorisation application in the EU voluntarily, intended for datopotamab deruxtecan.
Pharmaceutical Technology23 小时
LM-302 by Bristol-Myers Squibb for Esophageal Cancer: Likelihood of Approval
LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase I drugs for Esophageal Cancer have an 80% phase transition ...
Pharmaceutical Technology23 小时
Vemurafenib by F. Hoffmann-La Roche for Craniopharyngioma: Likelihood of Approval
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Craniopharyngioma. According to GlobalData, Phase II drugs for Craniopharyngioma does not have ...
Pharmaceutical Technology23 小时
Vemurafenib by F. Hoffmann-La Roche for Sarcomas: Likelihood of Approval
Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Sarcomas. According to GlobalData, Phase II drugs for Sarcomas have a 27% phase transition success rate ...
Pharmaceutical Technology23 小时
Rostaporfin by TuHURA Biosciences for Metastatic Breast Cancer: Likelihood of Approval
Rostaporfin is under clinical development by TuHURA Biosciences and currently in Phase III for Metastatic Breast Cancer.
Pharmaceutical Technology1 天
ACTUS-101 by Asklepios BioPharmaceutical for Pompe Disease: Likelihood of Approval
ACTUS-101 is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Pompe Disease.
Pharmaceutical Technology1 天
Gamma-PN by GPN Vaccines for Streptococcal Pneumonia: Likelihood of Approval
GPN Vaccines, formerly GPN Vaccines, is a clinical-stage company focused on creating vaccines that offer robust protection against bacterial pathogens. It develops vaccines to protect adults and ...
Pharmaceutical Technology1 天
EXO-CD24 by Nano24med for Acute Respiratory Distress Syndrome: Likelihood of Approval
EXO-CD24 is under clinical development by Nano24med and currently in Phase II for Acute Respiratory Distress Syndrome.
Pharmaceutical Technology1 天
S-309309 by Shionogi for Obesity: Likelihood of Approval
S-309309 is under clinical development by Shionogi and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success rate (PTSR) indication ...
Pharmaceutical Technology1 天
Odronextamab by Regeneron Pharmaceuticals for Marginal Zone B-cell Lymphoma: Likelihood of ...
Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Marginal Zone B-cell Lymphoma.